Monday, March 30, 2009

[StemCells] A talk about Human Embryonic Stem Cells in Cancer Treatment

James Alexander Thomson is an American developmental biologist who is best known
for deriving the first human embryonic stem cell line. He serves as director of
regenerative biology at the Morgridge Institute for Research in Madison,
Wisconsin, and is a professor at the University of Wisconsin School of Medicine
and Public Health.He is one of the leading scientific innovators in stem cell
research.

http://bioisolutions.blogspot.com/2009/03/human-embryonic-stem-cells-in-cancer.html

__._,_.___
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:

Children's Neurobiological Solutions
http://www.CNSfoundation.org/

Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123

The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Recent Activity
Visit Your Group
Give Back

Yahoo! for Good

Get inspired

by a good cause.

Y! Toolbar

Get it Free!

easy 1-click access

to your groups.

Yahoo! Groups

Start a group

in 3 easy steps.

Connect with others.

.

__,_._,___

Saturday, March 28, 2009

[StemCells] have a 'new' pancreas (people)

University of Miami trials give diabetics reason for hope
Clinical trials overseen by the University of Miami's Diabetes Research Center
show dramatic results in treatment of type 2 diabetes.
BY FRED TASKER
tasker@MiamiHerald.com
Human trials under way at the University of Miami and other hospitals in Europe,
Asia and Latin America using immature adult stem cells are showing promise for
people with type 2 diabetes.

In a UM clinical trial recently published in the online journal Cell
Transplantation, 25 patients achieved better insulin production, lower
blood-sugar levels and reduced need for insulin injections.

In the trial, still in its pilot stage, doctors extracted immature adult stem
cells from the patients' own bone marrow, purified and concentrated them, and
injected them into arteries near the pancreas. They then put the patients into
hyperbaric oxygen chambers like those used for divers with decompression
sickness -- also called the ''bends'' -- and subjected them to 10 hours of pure
oxygen at 2.4 times the atmospheric pressure at ground level.

Researchers believe the high-pressure oxygen pulled extra stem cells from the
patients' bone marrow, adding to the stem cells injected near the pancreas. They
say the immature stem cells developed into pancreatic cells, regenerating the
pancreas' ability to produce natural insulin.

''This could be very important,'' said Dr. Camillo Ricordi, director of the Cell
Transplant Center and the Diabetes Research Institute at UM. ``It could be an
improved treatment for diabetes, substantially ameliorating type 2 and
preventing the complications of the disease.''

Nearly 8 percent of the U.S. population -- 24 million people -- has diabetes,
which can cause problems for the eyes, kidneys, nerves and heart, according to
the Centers for Disease Control and Prevention.

Ricordi cautioned that the optimistic findings come from small pilot studies
involving only dozens of patients, and three to four more years of research are
needed before practical treatments might start.

''We always have to avoid hype and be careful not to put too much hope in pilot
trials,'' Ricordi said. ``But the first results are really promising.''

Two more successful trials over three or four years would be needed before the
FDA might approve the treatment. The studies, coordinated by UM's Diabetes
Research Institute, will also take place at the Karolinska Institutet in
Stockholm, Stem Cell Argentina in Buenos Aires and other institutions.
http://www.miamiherald.com/living/story/971932.html

__._,_.___
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:

Children's Neurobiological Solutions
http://www.CNSfoundation.org/

Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123

The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Recent Activity
Visit Your Group
Give Back

Yahoo! for Good

Get inspired

by a good cause.

Y! Toolbar

Get it Free!

easy 1-click access

to your groups.

Yahoo! Groups

Start a group

in 3 easy steps.

Connect with others.

.

__,_._,___

[StemCells] UofMiama's T2 diabetes pancreas regeneration results

University of Miami trials give diabetics reason for hope
Clinical trials overseen by the University of Miami's Diabetes Research Center show dramatic results in treatment of type 2 diabetes.
BY FRED TASKER
tasker@MiamiHerald.com
Human trials under way at the University of Miami and other hospitals in Europe, Asia and Latin America using immature adult stem cells are showing promise for people with type 2 diabetes.

In a UM clinical trial recently published in the online journal Cell Transplantation, 25 patients achieved better insulin production, lower blood-sugar levels and reduced need for insulin injections.

In the trial, still in its pilot stage, doctors extracted immature adult stem cells from the patients' own bone marrow, purified and concentrated them, and injected them into arteries near the pancreas. They then put the patients into hyperbaric oxygen chambers like those used for divers with decompression sickness -- also called the ''bends'' -- and subjected them to 10 hours of pure oxygen at 2.4 times the atmospheric pressure at ground level.

Researchers believe the high-pressure oxygen pulled extra stem cells from the patients' bone marrow, adding to the stem cells injected near the pancreas. They say the immature stem cells developed into pancreatic cells, regenerating the pancreas' ability to produce natural insulin.

''This could be very important,'' said Dr. Camillo Ricordi, director of the Cell Transplant Center and the Diabetes Research Institute at UM. ``It could be an improved treatment for diabetes, substantially ameliorating type 2 and preventing the complications of the disease.''

Nearly 8 percent of the U.S. population -- 24 million people -- has diabetes, which can cause problems for the eyes, kidneys, nerves and heart, according to the Centers for Disease Control and Prevention.

Ricordi cautioned that the optimistic findings come from small pilot studies involving only dozens of patients, and three to four more years of research are needed before practical treatments might start.

''We always have to avoid hype and be careful not to put too much hope in pilot trials,'' Ricordi said. ``But the first results are really promising.''

Two more successful trials over three or four years would be needed before the FDA might approve the treatment. The studies, coordinated by UM's Diabetes Research Institute, will also take place at the Karolinska Institutet in Stockholm, Stem Cell Argentina in Buenos Aires and other institutions.
http://www.miamiherald.com/living/story/971932.html

__._,_.___
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:

Children's Neurobiological Solutions
http://www.CNSfoundation.org/

Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123

The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Recent Activity
Visit Your Group
Yahoo! Groups

Auto Enthusiast Zone

Love cars? Check out the

Auto Enthusiast Zone

Cat Groups

on Yahoo! Groups

discuss everything

related to cats.

Yahoo! Groups

Stay healthy

and discover other

people who can help.

.

__,_._,___

[StemCells] Have a 'new' body part, the Pentagon hopes

USA: PENTAGON MAKES PROGRESS IN LIMB REGENERATION RESEARCH
Print Send this article(AGI) - Washington, 26 Mar. – The Pentagon has made a first step forward in its research into ‘induced’ stem cells (those which do not come from embryos) to regenerate the amputated limbs of Iraq and Afghanistan veterans. Researchers finally managed to transform epithelial cells in laboratory animals.
The cells were reverted to their primeval state, a sort of blastema, a mass of undifferentiated cells capable of developing into new body parts. Blastemas are found in nature in salamanders and tritons, animals which are capable re-growing limbs and associated body functions in the event of amputation. The final objective, which is still distant, is to replicate this extraordinary ability. Wired reports that research will focus on stage two before the final objective is reached. Stage two is the transformation of the cell mass into muscle tissue. The discovery was made by the Worcester Polytechnic Institute (Wpi), which received 570,000 dollars from Darpa, the Pentagon’s research department. Professor Raymond Page explained that “The aim is that of effectively replacing lost muscle”. The Darpa project, named "Restorative Injury Repair", aims to “recover the full functionality of nerve and muscle tissues that have been damaged or loss because of combat wounds". The general programme was launched on April 20 of last year by the Pentagon which invested 250 million dollars over a period of five years. The military set up a new structure, the Armed Forces Institute of Regenerative Medicine (Afirm) to develop the new Japanese technique that is not object of controversy for the generation of stem cells by reverting adult epithelial cells from patients to a primeval state. This method produces stem cells which will not be rejected by the patient which would be exploited because of their capacity of transforming into any one of the 271 different types of tissue found in the human body.

http://www.agi.it/world/news/200903262107-cro-ren0099-art.html

__._,_.___
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:

Children's Neurobiological Solutions
http://www.CNSfoundation.org/

Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123

The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Recent Activity
Visit Your Group
Give Back

Yahoo! for Good

Get inspired

by a good cause.

Y! Toolbar

Get it Free!

easy 1-click access

to your groups.

Yahoo! Groups

Start a group

in 3 easy steps.

Connect with others.

.

__,_._,___

[StemCells] Fixed w/Fat

Fat-Derived Treatments Show Potential for Repairing Tendons and Torn Ligaments
By HEATHER CHAMBERS
Posted date: 3/30/200
San Diego Business Journal Staff

On-the-job injuries are commonplace on a working farm.

So when Buzz ruptured a kneecap tendon, he inevitably faced surgery and at least six months of downtime.

"His career was over; he was through," said John Doyle, owner of the 3-year-old male border collie that herds sheep on his 40-acre Poway ranch, near Ramona.

Convinced he'd have to retire the working dog and turn him over as someone's pet, Doyle discovered another option available through his veterinarian: stem cell therapy.

Following surgery to repair the shredded tendon, Buzz was well enough to return to work within six weeks after receiving three rounds of stem cell therapy, Doyle said.

"In two weeks you could see that he was healing very quickly," Doyle said. "He was able to do a lot more."

Poway-based Vet-Stem, which touts itself as a world leader in veterinary regenerative medicine, was first to commercialize the process using fat-derived stem cells.

By extracting roughly two tablespoons of fat from behind the dog's shoulder blade or belly, veterinarians can treat the animals with their own stem cells.
The process is simple: Veterinarians ship the animal's fat overnight to the Vet-Stem laboratories. There, workers isolate the fat from the stem cells and ship the stem cells back to the veterinarian overnight in a syringe.

Treatments vary in cost, ranging from $2,500 to $3,500, including anesthesia. Doyle's veterinarian, Dean Gahring, said the therapy can prove cost-effective in the long run for animals that would otherwise be put on anti-inflammatory drugs.

Research at the University of Pittsburgh in the late 1990s, and also UCLA, eventually led to the creation of Vet-Stem in 2002. CEO Bob Harman, a veterinarian and former biotech executive, saw potential in bringing stem cell therapies for animals to market.

Growth Opportunity

The privately held company took early cues from San Diego-based Cytori Therapeutics, which developed a bedside device that separates fat from stem cells during reconstructive or cosmetic surgery.

Toucan Capital of Maryland, which invests in early stage life sciences companies, provided $1 million in seed funding and Harman said the company has raised $5 million to date. It aims to reach a profit this summer, Harman said.
http://www.sdbj.com/industry_article.asp?aID=86569519.20355502.1762098.9577099.275411.295&aID2=135537

__._,_.___
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:

Children's Neurobiological Solutions
http://www.CNSfoundation.org/

Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123

The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Recent Activity
Visit Your Group
Yahoo! Groups

Weight Management Challenge

Join others who

are losing pounds.

Health Groups

for people over 40

Join people who are

staying in shape.

Group Charity

Be the Change

A citizen movement

to change the world

.

__,_._,___

[StemCells] have a 'new' trachea - she did, no rejection

Woman gets new trachea grown from her tissues
Stem Cell-Generated; 'Probability this lady will have a rejection is almost 0%': doctor
By Michael Kahn, Reuters

LONDON (Reuters) - A Colombian woman has received the world's first tailor-made trachea transplant, grown by seeding a donor organ with her own stem cells to prevent her body rejecting it, an international research team reported on Wednesday.

The success of the operation, performed in June using tissue generated from the woman's own bone marrow, raises the prospect that transplanting other organs may be possible without drugs to dampen the immune system, they said.

Doctors work hard to match tissue type when transplanting organs so that the body does not completely reject the new organ, but patients usually have to take immunosuppressants for the rest of their lives.

"The probability this lady will have a rejection is almost zero percent," Dr. Paolo Macchiarini, head of thoracic surgery at the Hospital Clinic, Barcelona who performed the transplant, told a news conference.

"The patient is enjoying a normal life with no signs of rejection after four months."

Claudia Castillo sought help after a case of tuberculosis destroyed part of her trachea -- the windpipe connected to the lungs -- and left her with breathing difficulties, prone to infections and unable to care for her two children.

The 30-year-old's only option other than the experimental surgery was for doctors to remove part of her lung -- a choice that would have seriously degraded her quality of life, the researchers said.

"It isn't just an issue of life, it is an issue of quality of life," said Martin Birchall, a surgeon at the University of Bristol, who helped treat Castillo.

'HYBRID ORGAN'
After finding a donor, the researchers first depleted the transplanted trachea of the donor's cells and then obtained bone marrow stem cells from Castillo they grew into cartilage cells.

Next, the team seeded these cells on the outside of the donor trachea using a device developed at Milan Polytechnic in Italy that incubated the cells. The researchers used the same device to make epithelial cells to construct the lining of the trachea.

This created a hybrid organ in a lab that Castillo's body would identify as its own and make immunosupressant drugs unnecessary, the researchers said.

Finally, the team grafted a 5 cm (1.97 inch) piece of the trachea onto Castillo's damaged left main bronchus, which connects the main windpipe to the left lung.

Castillo, who lives in Spain, had no complications from the surgery and left the hospital after 10 days. She is returning to normal activities and even called her doctors from a night club to say she had been out dancing all night, the researchers said.

"We believe this success has proved we are on the verge of a new age in surgical care," said Birchall, who predicted the technique could be applied to other hollow organs similar in structure, such as the bowel, bladder and reproductive tract.

(Reporting by Michael Kahn; Editing by Maggie Fox and Mark Trevelyan)

http://www.calgaryherald.com/Health/Woman+gets+trachea+grown+from+tissues/972436/story.html© Copyright (c) Reuters

__._,_.___
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:

Children's Neurobiological Solutions
http://www.CNSfoundation.org/

Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123

The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Recent Activity
Visit Your Group
Cat Groups

on Yahoo! Groups

discuss everything

related to cats.

Group Charity

Hands On Network

Volunteering has

never been so easy

Yahoo! Groups

w/ John McEnroe

Join the All-Bran

Day 10 Club.

.

__,_._,___

[StemCells] Have a 'new' heart

New hope may lie in
lab-created heart
Beating rat heart created in
university lab
Updated: Friday, 27 Mar 2009, 9:15 PM EDT
Published : Friday, 27 Mar 2009, 9:13 PM EDT

By Miriam Falco
ATLANTA, Georgia (CNN) - Creating a replacement heart for some of the sickest patients may be one step closer, if new research in rats pans out in humans.

Researchers at the University of Minnesota were able to create a beating heart using the outer structure of one heart and injecting heart cells from another rat.

Their findings are reported in the journal Nature Medicine.

Rather than building a heart from scratch, which has often been mentioned as possible use for stem cells, this procedure takes a heart and breaks it down to the outermost shell. It's similar to taking a house and gutting it, then rebuilding everything inside. In the human version, the patient's own cells would be used.

"We took a rat heart and used soap to wash out the cells of the heart," said Doris Taylor, director of the Center for Cardiovascular Repair, Medtronic Bakken professor of medicine and physiology and lead author of the study.

The process is called "decelluarization." To do this, Taylor and her team hung up the heart from a dead rat, introduced a regular soap solution into the top of the organ, and let gravity do the work. The soap moved through the heart's blood vessels, dissolving existing cells, which dropped out of the bottom. This process was repeated until only the outermost casing of the heart was left, resulting in a "white, almost gelatin-looking heart," Taylor explained. This would be the equivalent of the gutted house.

The rebuilding started with injecting new heart cells, in this case cells from baby lab rats, and pumping them through the heart. By treating the cells as heart cells would be treated and using a pacemaker to help them learn how to pump, they grew into a heart that could pump -- essentially rebuilding the organ's interior.

Taylor says they've already started experimenting with pig hearts, which are closer in size to human hearts and because pig hearts are already used for replacement parts for some human heart patients.

The goal is to increase options for human heart patients. The body would be less likely to reject an organ created from its own cells.

The research was partially funded by the University of Minnesota and a research grant from the Medtronic Corp.

According to the American Heart Association, more than 80 million Americans have some form of cardiovascular disease. Heart disease is the No. 1 cause of death in men and women in the United States each year, killing nearly 900,000 people in 2004.

Nearly 5 million Americans suffer from heart failure, usually the result of coronary artery disease caused by blocked arteries or high blood pressure.

Heart transplants are the last resort for end-stage heart disease, but there aren't enough organs to go around. Watch more in rebuilding a heart in a lab »

In 2006, only 2,192 heart transplants were performed, the American Heart Association said, but 4,000 to 5,000 more people needing a transplant didn't get one because of a lack of organs.

Growing new hearts for human beings "is still a ways off," said Dr. Robert Bonow, a past president of the American Heart Association. "It's interesting and could pay off if they got the cells to grow properly within the heart." But that still has to be seen. Taylor acknowledges that they have not yet implanted one of these beating hearts into a rat and tried to keep it alive by using the new heart.

Bonow also points out that for many patients, coronary heart disease can be prevented, by not smoking, controlling your diabetes, controlling your blood pressure and reducing the amount of artery blocking bad cholesterol, which are the leading causes of heart attacks, which weaken the heart and can lead a patient to need a new one.

If this research pans out for humans, Taylor said, many hearts that are currently unsuitable for transplant could be used for this procedure.

Currently, a donor heart must be transplanted within the maximum of four hours. Sometimes the suitable patient is more than four hours away. Doctors could use the organs that can't be transplanted in time to build the scaffolding to grow future hearts. Taylor thinks this could be done. Then, bone marrow cells or blood cells or cells taken from the patient's heart biopsy -- or possibly even stored umbilical cord blood cells -- could be injected into a heart scaffold to grow a new heart.

This is still a long way from human application. First these results have to be replicated in the larger pig hearts Those experiments are under way at the University of Minnesota.

If their research continues as planned, Taylor said she could imagine approaching the Food and Drug Administration in three to five years to discuss the possibility of human clinical trials.

Robert Nerem, director of the Institute for Bioengineering and Bioscience at the Georgia Institute of Technology, said the new research is "exciting and has enormous potential, but clearly more needs to be done."

Neerem doesn't think this research will lead to creating hearts for transplantation. "I just don't think that's where the world of myocardial repair is going," he said. Instead, he thinks the technology will be used to help create a patch to fix part of the heart. "Most patients, given the choice between transplant and repair, will choose repairs," Nerem said.

He also said the development has great potential for research purposes: to use such a heart to study what heart disease actually does to the organ, or for the pharmaceutical industry to develop new drugs.

"Hopefully this would lead to fewer animal studies, and nothing beats testing new drugs on a human cell," he said. "But human cells in a petri dish don't tell us much."


think that's where the world of myocardial repair is going," he said. Instead, he thinks the technology will be used to help create a patch to fix part of the heart. "Most patients, given the choice between transplant and repair, will choose repairs," Nerem said.

He also said the development has great potential for research purposes: to use such a heart to study what heart disease actually does to the organ, or for the pharmaceutical industry to develop new drugs.

"Hopefully this would lead to fewer animal studies, and nothing beats testing new drugs on a human cell," he said. "But human cells in a petri dish don't tell us much."

http://www.wwlp.com/dpp/health/heart_health/wwlp_cnn_health_newhopemaylieinlabcreatedheart_200903272110

__._,_.___
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:

Children's Neurobiological Solutions
http://www.CNSfoundation.org/

Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123

The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Recent Activity
Visit Your Group
Yahoo! Groups

Auto Enthusiast Zone

Auto Enthusiast Zone

Discover auto groups

Group Charity

Be the Change

A citizen movement

to change the world

Yahoo! Groups

Do More For Cats Group

Connect and share with

cat owners like you

.

__,_._,___

Friday, March 27, 2009

[StemCells] Neural proliferation/death control

Period 2 regulates neural stem/progenitor cell proliferation in the adult hippocampus

Newborn granule neurons are generated from proliferating neural stem/progenitor cells and integrated into mature synaptic networks in the adult dentate gyrus (DG) of the hippocampus. Since light/dark variations of the mitotic index and DNA synthesis occur in many tissues, we wanted to unravel the role of the clock-controlled Period2 gene (mPer2) in timing cell cycle kinetics and neurogenesis in the adult DG.

Results: In contrast to the suprachiasmatic nucleus, we observed a non-rhythmic constitutive expression of mPER2 in the dentate gyrus. We provide evidence that mPER2 is expressed in proliferating NPCs and persists in early post-mitotic and mature newborn neurons from the adult DG.

In vitro and in vivo analysis of a mouse line mutant in the mPer2 gene (Per2Brdm1), revealed a higher density of dividing NPCs together with an increased number of immature newborn neurons populating the DG. However, we showed that the lack of mPer2 does not change the total amount of mature adult-generated hippocampal neurons, because of a compensatory increase in neuronal cell death.

Conclusion: Taken together, these data demonstrated a functional link between the constitutive expression of mPer2 and the intrinsic control of neural stem/progenitor cells proliferation, cell death and neurogenesis in the dentate gyrus of adult mice.

Author: Laurence Borgs, Pierre Beukelaers, Renaud Vandenbosch, Laurent Nguyen, Gustave Moonen, Pierre Maquet, Urs Albrecht, Shibeshih Belachew and Brigitte Malgrange
Credits/Source: BMC Neuroscience 2009, 10:30

http://7thspace.com/headlines/306202/period_2_regulates_neural_stemprogenitor_cell_proliferation_in_the_adult_hippocampus.html

__._,_.___
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:

Children's Neurobiological Solutions
http://www.CNSfoundation.org/

Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123

The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Recent Activity
Visit Your Group
Yahoo! Groups

Cats Group

Join a group for

cat owners like you

All-Bran

10 Day Challenge

Join the club and

feel the benefits.

Check out the

Y! Groups blog

Stay up to speed

on all things Groups!

.

__,_._,___

[StemCells] Promoting SC Mobilization in post-heart attack

Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack

SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported on an NIH-funded, pre-clinical study conducted by independent researchers at the University of Cincinnati entitled IGF-1--Overexpressing Mesenchymal Stem Cells Accelerate Bone Marrow Stem Cell Mobilization via Paracrine Activation of SDF-1 alpha/CXCR4 to Promote Myocardial Repair that was published in the American Heart Association's journal Circulation Research (Circ Res. 2008; 103(11): 1300-1308). The investigators reported that mesenchymal stem cells (MSCs) can be potentiated by introducing Ad5IGF-1 into the cells while they are being processed outside of the body or ex vivo. Upon reintroduction into the body, these Ad5IGF-1 activated stem cells substantially reduced heart attack related tissue damage (infarct size), caused extensive angiomyogenesis, and improved left ventricular ejection fraction and fractional shortening. MSCs not treated with Ad5IGF-1 had significantly less therapeutic effect in this preclinical model of heart attack. The authors concluded that the observed synergy between MSCs and Ad5IGF-1 in myocardial regeneration after a heart attack may be due to IGF-1-induced release of various cytokines and chemokines, including SDF-1 alpha, contributing to massive stem cell mobilization from the bone marrow and their increased homing in the injured heart muscle. The full article can be accessed at www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2640486.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

"Recent findings indicate that mesenchymal stem cells, which are processed ex vivo before reintroduction into the body, tend to loose certain capabilities required for effective binding and retention within injured heart tissue such as that occurring after a heart attack. We believe that the effectiveness of these stem cells can be substantially improved through a targeting mechanism that involves the binding of the CXC chemokine receptor 4 (found on these stem cells in the bone marrow but reduced after ex vivo expansion) with the stromal-derived factor-1 alpha ligand that is expressed in ischemic heart tissue following a heart attack. This suggests that treatment of mesenchymal stem cells ex vivo with an Ad5IGF-1 biologic, such as Cardium's Corgentin product candidate, will lead to local production of insulin-like growth factor-1 protein to enhance this process and amplify the delivery and retention of stem cells within injured heart tissue. The recently-published research findings from the University of Cincinnati provide independent support of this possible mechanism of action and underscore the potential use of Cardium's Corgentin candidate in stem cell therapies aimed at the treatment of heart attack and other indications," stated Cardium's Chief Scientific Officer, Gabor M. Rubanyi, M.D., Ph.D.

"Cardium has been developing a portfolio of innovative DNA-based growth factor therapeutics for cardiovascular and related applications. Our Corgentin (Ad5IGF-1) product candidate is designed to lessen tissue injury and promote myocardial repair and restoration following a heart attack," noted Christopher J. Reinhard, Cardium's Chief Executive Officer. "The well-documented biological properties of IGF-1 protein include the inhibition of programmed cell death or apoptosis, adaptive cardiomyocyte hypertrophy, proliferation of cardiac progenitor cells and angiogenesis. These observations provide a strong scientific rationale for the clinical development of an IGF-1 based therapy.

"This new study provides important insights into the potential synergies obtainable when mesenchymal stem cells are potentiated ex vivo by Ad5IGF-1 and suggest that Corgentin may be able to substantially improve stem cell approaches to the treatment of important disease conditions such as a heart attack. Based on the large body of scientific evidence supporting IGF-1's safety, its potentially beneficial effects in promoting tissue repair and regeneration, and its potential for promoting stem cell responses in vivo, we believe that Corgentin may be an important product candidate for the treatment of heart attack and other cardiovascular indications, including approaches based on the use of stem cells," concluded Mr. Reinhard.

About Cardium

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications.

Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and patient temperature modulation, including InnerCool's new RapidBlue(TM) System and its CoolBlue(TM) System, please visit www.innercool.com.

Cardium also has two biologic candidates in clinical development. Cardium's Tissue Repair Company subsidiary (TRC) is focused on the development of growth factor therapeutics for the treatment of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix(TM) (GAM) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit www.t-r-co.com.

Cardium's Generx(R) product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based growth factor therapeutic designed for potential application by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit www.cardiumthx.com or view its most recent Annual Report at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.

http://news.prnewswire.com/DisplayReleaseContent.aspx?ACCT=104&STORY=/www/story/03-27-2009/0004995902&EDATE=


__._,_.___
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:

Children's Neurobiological Solutions
http://www.CNSfoundation.org/

Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123

The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Recent Activity
Visit Your Group
Give Back

Yahoo! for Good

Get inspired

by a good cause.

Y! Toolbar

Get it Free!

easy 1-click access

to your groups.

Yahoo! Groups

Start a group

in 3 easy steps.

Connect with others.

.

__,_._,___


about stem cell research
adult stem cell
adult stem cell research
adult stem cells
against stem cell
against stem cell research
anti stem cell
anti stem cell research
autologous stem cell
autologous stem cell transplant
benefits of stem cell research
blood stem cells
bone marrow stem cells
bush stem cell
california stem cell
cancer stem cell
cancer stem cells
cell stem cell
cons of stem cell research
cord blood stem cell
cord blood stem cells
cord stem cells
diabetes stem cell
embryonic stem cell
embryonic stem cell research
embryonic stem cells
for stem cell research
funding for stem cell research
harvard stem cell
harvard stem cell institute
hematopoietic stem cell
hematopoietic stem cells
history of stem cell research
human embryonic stem cell
human embryonic stem cell research
human embryonic stem cells
international stem cell
mesenchymal stem cell
mesenchymal stem cells
neural stem cell
neural stem cells
nih stem cell
pluripotent stem cells
pro stem cell
pro stem cell research
pros and cons of stem cell
pros and cons of stem cell research
stem cell
stem cell bank
stem cell bill
stem cell biology
stem cell companies
stem cell conference
stem cell controversy
stem cell cures
stem cell debate
stem cell differentiation
stem cell ethics
stem cell funding
stem cell heart
stem cell information
stem cell institute
stem cell line
stem cell lines
stem cell news
stem cell policy
stem cell reasearch
stem cell reaserch
stem cell reseach
stem cell research
stem cell research articles
stem cell research bill
stem cell research controversy
stem cell research debate
stem cell research enhancement act
stem cell research ethics
stem cell research facts
stem cell research funding
stem cell research pros
stem cell research pros and cons
stem cell reserach
stem cell reserch
stem cell technologies
stem cell technology
stem cell therapy
stem cell transplant
stem cell transplantation
stem cell transplants
stem cell treatment
stem cell treatments
stem cell veto
stem cells
stem cells research
support stem cell research
types of stem cells
umbilical cord stem cells
what are stem cells
what is a stem cell
what is stem cell
what is stem cell research